These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 17257889)

  • 21. A possible relationship between the anti-cancer potency of photodynamic therapy using the novel photosensitizer ATX-s10-Na(II) and expression of the vascular endothelial growth factor in vivo.
    Okunaka T; Usuda J; Ichinose S; Hirata H; Ohtani K; Maehara S; Inoue T; Imai K; Kubota M; Tsunoda Y; Kuroiwa Y; Tsutsui H; Furukawa K; Nishio K; Kato H
    Oncol Rep; 2007 Sep; 18(3):679-83. PubMed ID: 17671719
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of vascular endothelial growth factor in human monocyte/macrophages stimulated with lipopolysaccharide.
    Itaya H; Imaizumi T; Yoshida H; Koyama M; Suzuki S; Satoh K
    Thromb Haemost; 2001 Jan; 85(1):171-6. PubMed ID: 11204570
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metabolic properties and photosensitizing responsiveness of mono-L-aspartyl chlorin e6 in a mouse tumor model.
    Ferrario A; Kessel D; Gomer CJ
    Cancer Res; 1992 May; 52(10):2890-3. PubMed ID: 1581904
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mono-L-aspartyl chlorin e6 (NPe6) and hematoporphyrin derivative (HpD) in photodynamic therapy administered to a human cholangiocarcinoma model.
    Wong Kee Song LM; Wang KK; Zinsmeister AR
    Cancer; 1998 Jan; 82(2):421-7. PubMed ID: 9445202
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Photodynamic therapy for human oral squamous cell carcinoma and xenografts using a new photosensitizer, PAD-S31.
    Date M; Sakata I; Fukuchi K; Ohura K; Azuma Y; Shinohara M; Matsuzaki K; Namiki Y; Takahashi H
    Lasers Surg Med; 2003; 33(1):57-63. PubMed ID: 12866122
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Photodynamic therapy of intestinal tumors with mono-L-aspartyl chlorin e6 (NPe6): a basic study.
    Kikuchi T; Asakura T; Aihara H; Shiraki M; Takagi S; Kinouchi Y; Aizawa K; Shimosegawa T
    Anticancer Res; 2003; 23(6C):4897-900. PubMed ID: 14981942
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular determinants of photodynamic therapy for lung cancers.
    Usuda J; Ichinose S; Ishizumi T; Ohtani K; Inoue T; Maehara S; Imai K; Shima K; Ohira T; Kato H; Ikeda N
    Lasers Surg Med; 2011 Sep; 43(7):591-9. PubMed ID: 22057486
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Killing tumor cells: the effect of photodynamic therapy using mono-L-aspartyl chlorine and NS-398.
    Harvey EH; Webber J; Kessel D; Fromm D
    Am J Surg; 2005 Mar; 189(3):302-5. PubMed ID: 15792755
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of MAPK signaling pathways enhances cell death induced by 5-Aminolevulinic acid-photodynamic therapy in skin squamous carcinoma cells.
    Ge X; Liu J; Shi Z; Jing L; Yu N; Zhang X; Jiao Y; Wang Y; Li PA
    Eur J Dermatol; 2016 Apr; 26(2):164-72. PubMed ID: 27032574
    [TBL] [Abstract][Full Text] [Related]  

  • 30. mTHPC-mediated photodynamic treatment up-regulates the cytokines VEGF and IL-1alpha.
    Dabkeviciene D; Sasnauskiene A; Leman E; Kvietkauskaite R; Daugelaviciene N; Stankevicius V; Jurgelevicius V; Juodka B; Kirveliene V
    Photochem Photobiol; 2012; 88(2):432-9. PubMed ID: 22171990
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cyclooxygenase-2 expression induced by photofrin photodynamic therapy involves the p38 MAPK pathway.
    Luna M; Wong S; Ferrario A; Gomer CJ
    Photochem Photobiol; 2008; 84(2):509-14. PubMed ID: 18282182
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of hypericin-mediated photodynamic therapy on the expression of vascular endothelial growth factor in human nasopharyngeal carcinoma.
    Bhuvaneswari R; Gan YY; Yee KK; Soo KC; Olivo M
    Int J Mol Med; 2007 Oct; 20(4):421-8. PubMed ID: 17786271
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Photobleaching of mono-L-aspartyl chlorin e6 (NPe6): a candidate sensitizer for the photodynamic therapy of tumors.
    Spikes JD; Bommer JC
    Photochem Photobiol; 1993 Sep; 58(3):346-50. PubMed ID: 8234467
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictive factor for photodynamic therapy effects on oral squamous cell carcinoma and oral epithelial dysplasia.
    Uehara M; Ikeda H; Nonaka M; Sumita Y; Nanashima A; Nonaka T; Asahina I
    Arch Oral Biol; 2011 Nov; 56(11):1366-72. PubMed ID: 21596370
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of photodynamic therapy using a fractionated dosing of mono-L-aspartyl chlorin e6 in a murine tumor.
    Webber J; Leeson B; Fromm D; Kessel D
    J Photochem Photobiol B; 2005 Feb; 78(2):135-40. PubMed ID: 15664500
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcome of photodynamic therapy using NPe6 for bronchogenic carcinomas in central airways >1.0 cm in diameter.
    Usuda J; Ichinose S; Ishizumi T; Hayashi H; Ohtani K; Maehara S; Ono S; Honda H; Kajiwara N; Uchida O; Tsutsui H; Ohira T; Kato H; Ikeda N
    Clin Cancer Res; 2010 Apr; 16(7):2198-204. PubMed ID: 20332318
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Concomitant treatment with temozolomide enhances apoptotic cell death in glioma cells induced by photodynamic therapy with talaporfin sodium.
    Miki Y; Akimoto J; Omata H; Moritake K; Hiranuma M; Hironaka C; Fujiwara Y; Beppu M
    Photodiagnosis Photodyn Ther; 2014 Dec; 11(4):556-64. PubMed ID: 25262961
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [EphA2 mediated vascular endothelial growth factor expression via the p38 MAPK signaling pathway in squamous cell carcinoma of the head and neck].
    Liu Y; Tan HL; Li G; Yu CY; Su ZW; Ren SL; Zhu GC; Qiu YZ; Tian YQ; Zhang X
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2013 Mar; 48(3):229-33. PubMed ID: 23755789
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cyclooxygenase-2 is a possible target of treatment approach in conjunction with photodynamic therapy for various disorders in skin and oral cavity.
    Akita Y; Kozaki K; Nakagawa A; Saito T; Ito S; Tamada Y; Fujiwara S; Nishikawa N; Uchida K; Yoshikawa K; Noguchi T; Miyaishi O; Shimozato K; Saga S; Matsumoto Y
    Br J Dermatol; 2004 Aug; 151(2):472-80. PubMed ID: 15327557
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Methylglyoxal and advanced glycation end-products promote cytokines expression in peritoneal mesothelial cells via MAPK signaling.
    Hong FY; Bao JF; Hao J; Yu Q; Liu J
    Am J Med Sci; 2015 Feb; 349(2):105-9. PubMed ID: 25581570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.